For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 37,353 | 26,480* | 39,824 | 37,638 |
| General and administrative | 6,943 | 7,019* | 6,764 | 8,268 |
| Total operating expenses | 44,296 | 33,499 | 46,588 | 45,906 |
| Loss from operations | -44,296 | -33,499* | -46,588 | -45,906 |
| Interest income | 1,076 | 1,204* | 1,808 | 1,410 |
| Interest expense | 636 | 272* | 584 | 571 |
| Other income, net | 341 | -297* | 498 | -61 |
| Net loss | -43,515 | -32,864* | -44,866 | -45,128 |
| Net unrealized gain on available-for-sale investments, net of tax | -25 | -9* | 22 | 1 |
| Net comprehensive loss | -43,540 | -32,874 | -44,844 | -45,127 |
| Basic EPS | -0.39 | -5.479 | -0.44 | -0.73 |
| Diluted EPS | -0.39 | -0.525* | -0.44 | -0.73 |
| Basic Average Shares | 112,025,474 | 6,000,000 | - | - |
| Diluted Average Shares | 112,025,474 | - | - | - |
Cabaletta Bio, Inc. (CABA)
Cabaletta Bio, Inc. (CABA)